Genotyping Assay Market Report 2026

The genotyping assay market size has grown exponentially in recent years. It will grow from $41.31 billion in 2025 to $50.86 billion in 2026 at a compound annual growth rate (CAGR) of 23.1%. The growth in the historic period can be attributed to development of pcr techniques, growth of molecular diagnostics, pharmaceutical safety testing needs, early assay commercialization, academic research demand.

The genotyping assay market size is expected to see exponential growth in the next few years. It will grow to $116.09 billion in 2030 at a compound annual growth rate (CAGR) of 22.9%. The growth in the forecast period can be attributed to increased biomarker-driven drug development, automation in laboratories, expansion of companion diagnostics, demand for rapid assays, regulatory validation. Major trends in the forecast period include rising demand for snp-based assays, increased adoption of pcr-based genotyping, growth of high-sensitivity genotyping assays, expansion of genotyping assays in drug development, integration of automation in assay processing.

The rising prevalence of genetic disorders is expected to drive the growth of the genotyping assay market in the coming years. Genetic disorders are medical conditions caused by abnormalities or mutations in an individual’s DNA. Genotyping assays compare the DNA of affected individuals with that of healthy individuals to identify changes, revealing specific genetic mutations or variations associated with particular disorders. For example, in June 2023, Gene People, a UK-based registered charity supporting individuals with genetic conditions, reported that one in every 25 children in the UK has a genetic disorder, affecting approximately 30,000 newborns and young children, as well as more than 2.4 million children and adults annually. Consequently, the increasing prevalence of genetic disorders is fueling growth in the genotyping assay market.

Key companies in the genotyping assay market are developing innovations in genomic research, such as CE-IVD marked assays to detect treatment-resistant strains of HIV-1. The CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit is a Sanger sequencing-based assay designed to examine positive HIV samples and identify genetic variants that may resist standard antiretroviral therapies. For instance, in January 2023, Thermo Fisher Scientific, a US-based company, launched the CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit. The system identifies treatment-resistant HIV-1 strains and features genomic mutation assessment using HIV RNA, drug resistance detection, gold-standard Sanger sequencing technology, and clinical usability. The launch enhances detection of treatment-resistant HIV-1 strains by providing ready-to-use reagents and controls, meeting regulatory standards, delivering high performance, and maintaining compatibility with existing sequencing platforms and workflows.

In August 2023, Transnetyx Inc., a US-based biotechnology company, acquired Laragen Inc. for an undisclosed amount. Through this acquisition, Transnetyx aims to expand its portfolio to include sequencing and next-generation sequencing (NGS) services, providing large research institutions with greater access to advanced genetic services. Laragen Inc. is a US-based biotechnology company specializing in sequencing and genotyping assay services for DNA.

Major companies operating in the genotyping assay market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Danaher Corporation, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., Qiagen NV, BGI Genomics, LGC Biosearch Technologies, GenScript Biotech, Promega Corporation, Luminex Corporation, Integrated DNA Technologies Inc., 23andMe Inc., Novogene Corporation, Oxford Nanopore Technologies plc, GenMark Diagnostics Inc., Macrogen Inc., Pacific Biosciences of California Inc., Standard BioTools Inc., Genewiz Inc., New England Biolabs.

North America was the largest region in the genotyping assay market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genotyping assay market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genotyping assay market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the genotyping assay market by increasing costs of imported reagents, assay kits, and laboratory instruments. Diagnostic laboratories and pharmaceutical companies are most affected due to dependence on imported consumables. These tariffs increase assay costs by raising recurring consumable expenses and equipment servicing costs. However, they encourage local reagent production, supporting regional chemical manufacturing and supply security.

The genotyping assay market research report is one of a series of new reports that provides genotyping assay market statistics, including genotyping assay industry global market size, regional shares, competitors with a genotyping assay market share, detailed genotyping assay market segments, market trends and opportunities, and any further data you may need to thrive in the genotyping assay industry. This genotyping assay market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A genotyping assay is a laboratory method used to determine an individual’s genetic composition at specific loci or positions within their DNA. It detects and analyzes genetic variations, such as single nucleotide polymorphisms (SNPs) or insertions and deletions, present in a person’s genome.

The primary products and services in genotyping assays include reagents and kits, genotyping services, instruments, and bioinformatics. Reagents and kits are crucial components in a variety of scientific and laboratory applications, especially in molecular biology, chemistry, and diagnostics. The technologies employed include microarrays, polymerase chain reaction (PCR), sequencing, capillary electrophoresis, matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry, and others. These are applied by various end users, including pharmacogenomics, personalized medicine and diagnostics, animal genetics, agricultural biotechnology, research and diagnostic laboratories, and academic institutions.

The genotyping assay market includes revenues earned by entities that provide genotyping assay services such as single nucleotide polymorphisms (SNPs) genotyping, short tandem repeats (STRs) genotyping, whole genome genotyping, and clinical genotyping services. The market value includes the value of related goods sold by the service provider or included within the service offering. The genotyping assay market consists of sales of products such as polymerase chain reaction (PCR) primers, SNP genotyping kits, DNA extraction kits, and microarray chips. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.